AbCellera Presents New Data on T-Cell Engager Platform at AACR 2023
17 Aprile 2023 - 3:10PM
Business Wire
- In-depth characterization of CD3-binding antibodies reveals
molecules with binding and functional properties that are
differentiated from antibodies commonly used for T-cell engager
development
- Discovery of antibodies with high specificity for a peptide-MHC
complex demonstrates capabilities for development of T-cell
engagers against challenging cancer targets
AbCellera (Nasdaq: ABCL) today presented new data on its T-cell
engager (TCE) platform in two poster presentations at the American
Society for Cancer Research (AACR) Annual Meeting 2023, which is
being held at the Orange County Convention Center in Orlando,
Florida, from April 14 to 19, 2023. AbCellera debuted its TCE
platform at AACR 2022 with data describing the diversity of its
CD3-binding antibodies. Presentations at AACR 2023 illustrated how
AbCellera streamlines the development of TCEs with optimal
functional properties for diverse tumor targets.
“T-cell engagers are amongst the most promising new modalities
in cancer therapy. The robust characterization of our novel
CD3-binding antibodies in both mono- and bispecific formats
illustrates that we can engineer optimal TCEs by fine-tuning tumor
cell killing and cytokine release,” says Bo Barnhart, Ph.D., VP,
Translational Research at AbCellera. “Combined with our ability to
discover antibodies against some of the most challenging cancer
targets, our engine can enable the development of custom-built TCEs
for a wide range of cancers.”
First, AbCellera demonstrated that its panel of novel, fully
human CD3-binding antibodies can build optimized TCEs that have
functional profiles superior to benchmark molecules. The
presentation included:
- A comprehensive data package on a panel of CD3-binding
antibodies, including binding and functional comparisons to
molecules commonly used for TCE development.
- Two proof-of-concept studies in which novel CD3-binding
antibodies were used to engineer TCEs for different tumor targets.
The resulting TCEs included bispecific antibodies with high
potencies and low cytokine release in in vitro assays. Differences
in T-cell function across tumor targets emphasized the importance
of selecting the right CD3- and tumor-binding antibodies for an
optimal TCE. These data demonstrate how AbCellera’s novel
CD3-binding antibodies enable development of custom-built TCEs for
different tumor targets.
In another poster, AbCellera described the discovery of highly
specific and developable antibodies against a validated
peptide-major histocompatibility complex (pMHC) tumor target.
Melanoma-associated antigen 4 (MAGE-A4) is a tumor-specific antigen
expressed by many solid tumors, but not by most healthy tissue.
Effectively targeting pMHCs presenting tumor-specific antigens with
TCEs could unlock tumor targets that are expressed inside the cell,
which are generally inaccessible with this modality. AbCellera used
its antibody discovery and development engine to generate
antibodies that bind to MAGE-A4-pMHC. Strategic selection and
pairing of AbCellera’s target- and CD3-binding antibodies has the
potential to power the discovery of optimal TCEs targeting
MAGE-A4-pMHC.
“In late 2021, we recognized a gap that was preventing powerful
TCE cancer treatments from making it to patients and felt confident
that our antibody discovery and development engine could provide
the solution,” said Murray McCutcheon, Ph.D., Senior VP,
Partnering. “In 18 months, we have developed a TCE discovery
platform and are leveraging the extensive datasets we’ve generated
to custom-build TCEs and help bring better cancer treatments to
patients faster.”
AbCellera’s poster presentations are available for viewing
here.
About T-Cell Engagers
CD3 T-cell engagers are bispecific antibodies that guide the
immune system to find and eliminate cancer cells by binding both
cancer-killing T cells and tumor targets at the same time.
Developing effective T-cell engagers requires two parental
antibodies — a CD3-binding arm that fine-tunes T cell activation
and a tumor-binding arm with high specificity for cancer cells. The
small number of available CD3-binding antibodies that can
effectively fine-tune T-cell responses has been a barrier to T-cell
engager development. To address this barrier, AbCellera developed a
complete T-cell engager platform that includes fully human,
developable CD3-binding antibodies with unique binding and
functional properties. By combining these antibodies with
OrthoMabTM, its clinically validated multispecific engineering
platform, and its antibody discovery and development engine,
AbCellera’s T-cell engager platform is breaking the barriers of
conventional discovery to bring new cancer medicines to the clinic
faster.
About AbCellera Biologics Inc.
AbCellera is breaking the barriers of conventional antibody drug
discovery to bring better medicines to patients, sooner.
AbCellera’s engine integrates expert teams, technology, and
facilities with the data science and automation needed to propel
antibody-based medicines from target to clinic in nearly every
therapeutic area with precision and speed. AbCellera provides
innovative biotechs and leading pharmaceutical companies with a
competitive advantage that empowers them to move quickly, reduce
cost, and tackle the toughest problems in drug development. For
more information, please visit www.abcellera.com.
AbCellera Forward-Looking Statements
This press release contains forward-looking statements,
including statements made pursuant to the safe harbor provisions of
the Private Securities Litigation Reform Act of 1995. The
forward-looking statements are based on management’s current
beliefs and assumptions and on information currently available to
management. All statements contained in this release other than
statements of historical fact are forward-looking statements,
including statements regarding our ability to develop,
commercialize and achieve market acceptance of our current and
planned products and services, our research and development
efforts, and other matters regarding our business strategies, use
of capital, results of operations and financial position, and plans
and objectives for future operations.
In some cases, you can identify forward-looking statements by
the words “may,” “will,” “could,” “would,” “should,” “expect,”
“intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,”
“project,” “potential,” “continue,” “ongoing” or the negative of
these terms or other comparable terminology, although not all
forward-looking statements contain these words. These statements
involve risks, uncertainties and other factors that may cause
actual results, levels of activity, performance, or achievements to
be materially different from the information expressed or implied
by these forward-looking statements. These risks, uncertainties and
other factors are described under "Risk Factors," "Management's
Discussion and Analysis of Financial Condition and Results of
Operations" and elsewhere in the documents we file with the
Securities and Exchange Commission from time to time. We caution
you that forward-looking statements are based on a combination of
facts and factors currently known by us and our projections of the
future, about which we cannot be certain. As a result, the
forward-looking statements may not prove to be accurate. The
forward-looking statements in this press release represent our
views as of the date hereof. We undertake no obligation to update
any forward-looking statements for any reason, except as required
by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230414005467/en/
Inquiries Media: Jessica Yingling, Ph.D.;
media@abcellera.com, +1(236)521-6774 Business Development: Murray
McCutcheon, Ph.D.; bd@abcellera.com, +1(604)559-9005 Investor
Relations: Josephine Hellschlienger, Ph.D.; ir@abcellera.com,
+1(778)729-9116
Grafico Azioni AbCellera Biologics (NASDAQ:ABCL)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni AbCellera Biologics (NASDAQ:ABCL)
Storico
Da Lug 2023 a Lug 2024